Vaccines Market - Global Forecast to 2023: Increasing Company Initiatives to Enhance R&D are Driving the Vaccines Market
DUBLIN, Aug. 21, 2018 /PRNewswire/ --
Research and Markets
The "Vaccines Market by Technology, Disease, Route, Patient, Type - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%
Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the vaccines market.
This report segments the vaccines market into technology, type, disease indication, route of administration, patient type, and region. Based on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the vaccines market, in 2018. Rising prevalence of diseases and increasing government initiatives are the key factors driving the growth of this segment.
Based on the type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent vaccines segment is projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government and nongovernment initiatives to promote immunization are the key factors driving the growth of this segment.
Based on disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The meningococcal disease segment is expected to witness the highest growth during the forecast period. The growth of this segment is primarily attributed to high incidence of meningococcal disease and increasing government investments in meningococcal vaccination programs.
Based on route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment is expected to hold the largest share of the vaccines market, in 2018. The growth of this segment is attributed to benefits associated with this mode of administration such as faster absorption of medication in blood, and lower rate of injection site reactions.
Based on the patient type, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.
In 2018, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.
While North America is expected to dominate the market in 2018, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging economies such as India and China and rising disposable income.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Overview of the Vaccines Market
4.2 Vaccines Market, By Type, 2018-2023
4.3 Vaccines Market, By End User, 2018 vs 2023 (USD Billion)
4.4 Geographic Analysis: Vaccines Market, By Technology
4.5 Vaccines Market, By Route of Administration, 2018 vs 2023 (USD Billion)
4.6 Geographical Snapshot of the Vaccines Market
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.4.2 Product Recalls
6 Industry Insights
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 Hiv
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding
7 Vaccines Market, By Technology
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated and Subunit Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vaccines
7.6 Toxoid Vaccines
8 Vaccines Market, By Type
8.1 Introduction
8.2 Monovalent Vaccines
8.3 Multivalent Vaccines
9 Vaccines Market, By Disease Indication
9.1 Introduction
9.2 Pneumococcal Disease
9.3 DTP
9.4 Influenza
9.5 HPV
9.6 Meningococcal Disease
9.7 Polio
9.8 Rotavirus
9.9 Hepatitis
9.10 MMR
9.11 Varicella
9.12 Dengue
9.13 Herpes Zoster
9.14 Other Disease Indications
10 Vaccines Market, By Route of Administration
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.3 Oral Administration
10.4 Other Routes of Administration
11 Vaccines Market, By Patient Type
11.1 Introduction
11.2 Pediatric Patients
11.3 Adult Patients
12 Vaccines Market, By Region
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 RoE
12.4 Asia
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia (Roa)
12.5 Rest of the World (RoW)
13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Situation and Trends
13.3.1 Agreements, Partnerships, and Collaborations
13.3.2 Product Launches and Approvals
13.3.3 Acquisitions
13.3.4 Expansions
14 Company Profiles
- Astellas Pharma
- Bavarian Nordic
- Biological E
- CSL Limited
- Daiichi Sankyo Company
- Emergent Biosolutions
- Glaxosmithkline
- Johnson & Johnson
- Medimmune, LLC (A Subsidiary of Astrazeneca)
- Merck
- Mitsubishi Tanabe Pharma Corporation
- Panacea Biotec
- Pfizer
- Sanofi Pasteur
- Serum Institute of India
For more information about this report visit https://www.researchandmarkets.com/research/2lz5lb/vaccines_market?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article